CEO
Sujal Shah
Employees
66
Industry
Pharmaceutical Preparation Manufacturing
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
Loading...
Open
32.49
Mkt cap
3.7B
Volume
8.4M
High
32.50
P/E Ratio
-32.81
52-wk high
32.50
Low
32.48
Div yield
N/A
52-wk low
7.26
Portfolio Pulse from Benzinga Newsdesk
February 13, 2024 | 12:57 pm
Portfolio Pulse from Benzinga Newsdesk
February 13, 2024 | 10:51 am
Portfolio Pulse from Benzinga Newsdesk
February 13, 2024 | 10:49 am
Portfolio Pulse from Avi Kapoor
February 13, 2024 | 8:43 am
Portfolio Pulse from Avi Kapoor
February 12, 2024 | 5:30 pm
Portfolio Pulse from Benzinga Newsdesk
February 12, 2024 | 4:44 pm
Portfolio Pulse from Benzinga Newsdesk
February 12, 2024 | 3:43 pm
Portfolio Pulse from Avi Kapoor
February 12, 2024 | 3:22 pm
Portfolio Pulse from Benzinga Insights
February 12, 2024 | 3:10 pm
Portfolio Pulse from Vandana Singh
February 12, 2024 | 2:22 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.